Aspire BioPharma is now trading 5.35% down in pre-market at $8.50, with the decline appearing aligned with broader risk-off trading and no fresh company-specific announcement or filing identified for September 1, 2026.
- Japan’s 10-year government bond yield reached 3% for the first time since 1996.
- Geopolitical tensions and higher oil prices pressured global equities and raised interest-rate concerns.